Format

Send to

Choose Destination
Neurology. 2006 Feb 28;66(4):602-4.

Effects of a gamma-secretase inhibitor in a randomized study of patients with Alzheimer disease.

Author information

1
Eli Lilly and Company, Indianapolis, IN 46085, USA. esiemers@lilly.com

Abstract

LY450139 dihydrate, a gamma-secretase inhibitor, was studied in a randomized, controlled trial of 70 patients with Alzheimer disease. Subjects were given 30 mg for 1 week followed by 40 mg for 5 weeks. Treatment was well tolerated. Abeta(1-40) in plasma decreased by 38.2%; in CSF, Abeta(1-40) decreased by 4.42 +/- 9.55% (p = not significant). Higher drug doses may result in additional decreases in plasma Abeta concentrations and a measurable decrease in CSF Abeta.

[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for HighWire
Loading ...
Support Center